Objective To study the risk factors of myelosuppression after the chemotherapy in patients with malignant tumors,and to construct a Logistic regression prediction model based on the risk factors.Methods Clinical information of 80 chemotherapy patients from the First Affiliated Hospital of Kunming Medical University during 2021.01-2022.12 was anonymously collected,and the obtained clinical data were used for Logistic regression univariate analysis with the use of SPSS19.0 software to identify the risk factors related to chemotherapy induced myelosuppression.The risk factors were tested in Logistic multi-factor regression analysis and the Logistic regression analysis prediction models were constructed.In addition,clinical information of 40 patients was collected to test the prediction model,then the ROC curve,AUC value and Youden index were obtained.Results Univariate Logistic regression analysis showed that age,bone metastases,alanine aminotransferase(ALT),aspartate aminotransferase(AST),serum creatinine clearance(CCr),serum creatinine(Cr),concurrent radiotherapy(CRT),concurrent immunotherapy(IO),and the recent surgery were associated with the bone marrow suppression after the chemotherapy(P<0.05).The AUC values of the ROC curves of the corres-ponding models were 0.745,0.755 and 0.791,respectively,indicating that the risk of bone marrow suppression was higher when the predictive model p-value was greater than the above values.The Youden indices of the corresponding models were 0.677,0.713 and 0.769,respectively,indicating that the prediction performance of the model was better.Conclusion Age,serum creatinine clearance,liver function,the recent surgery,bone metastasis,concurrent radiotherapy/immunotherapy,and serum creatinine clearance are related to the incidence of chemotherapy induced myelosuppression.When p≥0.745(leukocytes),p≥0.755(platelets),and p≥0.791(anemia)through the predictive model calculations,the risk of leukocyte,platelets,and the anemia-related myelosuppression are significantly increased(≥95%),and appropriate preventive measures are recommended.

The orthobunyavirus is a major group of mosquito-borne viruses，mainly prevalent in the Americas，Europe，and Africa. It can cause severe human diseases（e.g.，encephalitis，hemorrhagic fever）and livestock abortions. Reverse genetics，as a powerful tool for viral genome research，has been widely applied to study viral gene functions，develop vaccines，and screen antiviral drugs. This review systematically presents the evolutionary history and applications of the reverse genetics system for orthobunyaviruses，providing critical insights into studies on the infection and transmission mechanisms of these viruses，as well as the development of novel vaccines and therapeutic agents.

The orthobunyavirus is a major group of mosquito-borne viruses，mainly prevalent in the Americas，Europe，and Africa. It can cause severe human diseases（e.g.，encephalitis，hemorrhagic fever）and livestock abortions. Reverse genetics，as a powerful tool for viral genome research，has been widely applied to study viral gene functions，develop vaccines，and screen antiviral drugs. This review systematically presents the evolutionary history and applications of the reverse genetics system for orthobunyaviruses，providing critical insights into studies on the infection and transmission mechanisms of these viruses，as well as the development of novel vaccines and therapeutic agents.

Objective:To retrieve and summarize relevant evidence on nutritional management in patients with diabetic foot ulcers.Methods:Databases and websites, including UpToDate, BMJ Best Practice, Joanna Briggs Institute Evidence-Based Practice Center, Cochrane Library, Medlive, PubMed, Embase, CINAHL, Wanfang Database, China National Knowledge Infrastructure, as well as the websites of the International Diabetic Foot and the International Diabetes Federation, were systematically searched for literature related to nutritional management in patients with diabetic foot ulcers. Records of guidelines, systematic reviews, evidence summaries, clinical decisions, expert consensus, and randomized controlled trials published from database establishment to June 30, 2023 were screened. Two researchers independently evaluated the search results and included eligible literature as per quality criteria.Results:This study ultimately included 31 pieces of publication, comprising 6 guidelines, 1 expert consensus, 9 systematic reviews, 1 best clinical practice, and 14 randomized controlled trials. A total of 35 pieces of evidence were summarized, covering the six domains of nutritional assessment, dietary methods, modes of nutritional support, nutrients, hydration, and nutrition education and follow-up for patients with diabetic foot ulcers.Conclusions:This study summarized the best evidence on nutritional management for patients with diabetic foot ulcers in a scientific and robust manner. Clinicians, management decision-makers, and policy implementers can develop individualized nutritional support plans for patients with diabetic foot ulcers based on actual conditions, to promote wound healing, improve patient physical and mental health and enhance patient quality of life.

Objective:To retrieve and summarize relevant evidence on nutritional management in patients with diabetic foot ulcers.Methods:Databases and websites, including UpToDate, BMJ Best Practice, Joanna Briggs Institute Evidence-Based Practice Center, Cochrane Library, Medlive, PubMed, Embase, CINAHL, Wanfang Database, China National Knowledge Infrastructure, as well as the websites of the International Diabetic Foot and the International Diabetes Federation, were systematically searched for literature related to nutritional management in patients with diabetic foot ulcers. Records of guidelines, systematic reviews, evidence summaries, clinical decisions, expert consensus, and randomized controlled trials published from database establishment to June 30, 2023 were screened. Two researchers independently evaluated the search results and included eligible literature as per quality criteria.Results:This study ultimately included 31 pieces of publication, comprising 6 guidelines, 1 expert consensus, 9 systematic reviews, 1 best clinical practice, and 14 randomized controlled trials. A total of 35 pieces of evidence were summarized, covering the six domains of nutritional assessment, dietary methods, modes of nutritional support, nutrients, hydration, and nutrition education and follow-up for patients with diabetic foot ulcers.Conclusions:This study summarized the best evidence on nutritional management for patients with diabetic foot ulcers in a scientific and robust manner. Clinicians, management decision-makers, and policy implementers can develop individualized nutritional support plans for patients with diabetic foot ulcers based on actual conditions, to promote wound healing, improve patient physical and mental health and enhance patient quality of life.

Objective:To evaluate the efficacy and safety of mitoxantrone hydrochloride liposome injection in the treatment of peripheral T-cell lymphoma (PTCL) in a real-world setting.Methods:This was a real-world ambispective cohort study (MOMENT study) (Chinese clinical trial registry number: ChiCTR2200062067). Clinical data were collected from 198 patients who received mitoxantrone hydrochloride liposome injection as monotherapy or combination therapy at 37 hospitals from January 2022 to January 2023, including 166 patients in the retrospective cohort and 32 patients in the prospective cohort; 10 patients in the treatment-na?ve group and 188 patients in the relapsed/refractory group. Clinical characteristics, efficacy and adverse events were summarized, and the overall survival (OS) and progression-free survival (PFS) were analyzed.Results:All 198 patients were treated with mitoxantrone hydrochloride liposome injection for a median of 3 cycles (range 1-7 cycles); 28 cases were treated with mitoxantrone hydrochloride liposome injection as monotherapy, and 170 cases were treated with the combination regimen. Among 188 relapsed/refractory patients, 45 cases (23.9%) were in complete remission (CR), 82 cases (43.6%) were in partial remission (PR), and 28 cases (14.9%) were in disease stabilization (SD), and 33 cases (17.6%) were in disease progression (PD), with an objective remission rate (ORR) of 67.6% (127/188). Among 10 treatment-na?ve patients, 4 cases (40.0%) were in CR, 5 cases (50.0%) were in PR, and 1 case (10.0%) was in PD, with an ORR of 90.0% (9/10). The median follow-up time was 2.9 months (95% CI 2.4-3.7 months), and the median PFS and OS of patients in relapsed/refractory and treatment-na?ve groups were not reached. In relapsed/refractory patients, the difference in ORR between patients with different number of treatment lines of mitoxantrone hydrochloride liposome injection [ORR of the second-line, the third-line and ≥the forth-line treatment was 74.4% (67/90), 73.9% (34/46) and 50.0% (26/52)] was statistically significant ( P = 0.008). Of the 198 PTCL patients, 182 cases (91.9%) experienced at least 1 time of treatment-related adverse events, and the incidence rate of ≥grade 3 adverse events was 66.7% (132/198), which was mainly characterized by hematologic adverse events. The ≥ grade 3 hematologic adverse events mainly included decreased lymphocyte count, decreased neutrophil count, decreased white blood cell count, and anemia; non-hematologic adverse events were mostly grade 1-2, mainly including pigmentation disorders and upper respiratory tract infection. Conclusions:The use of mitoxantrone hydrochloride liposome injection-containing regimen in the treatment of PTCL has definite efficacy and is well tolerated, and it is a new therapeutic option for PTCL patients.

Objective::Data comparing the outcomes of MiStent (Micell Technologies, Durham, North Carolina, USA) microcrystalline biodegradable polymer (BP) drug-eluting stent (DES) and those of another post-marketing BP-DES, TIVOLI (EssenTech, Beijing, China) are rare. This study sought to compare the angiographic efficacy and clinical outcomes of the microcrystalline BP sirolimus-eluting stent (SES) system MiStent and those of TIVOLI BP-SES.Methods::The DESSOLVE-C trial was a prospective, single-blinded, multicenter, randomized trial (NCT02448524), which randomly assigned patients with de novo coronary lesions to receive MiStent or TIVOLI BP-SES by a 1:1 ratio. The primary endpoint was a non-inferiority comparison of in-stent late lumen loss (LLL) by quantitative coronary angiography at 9 months. The secondary endpoint was device-related clinical cardiovascular composite events (target lesion failure (TLF), composite of cardiac death, target vessel myocardial infarction (MI), and clinically driven target lesion revascularization) and 1-year outcomes. Results::A total of 428 patients (216 patients in the MiStent group and 212 patients in the TIVOLI group) were enrolled and included in an intention-to-treat analysis. MiStent was not only non-inferior but superior to TIVOLI for in-stent LLL at 9 months ((0.23 ± 0.37) mm vs. (0.34 ± 0.48) mm, P for non-inferiority <0.001, P for superiority = 0.02). Although without significant difference, the rate of TLF in MiStent was quantitatively lower than that in TIVOLI (3.70% vs. 6.60%; P = 0.17). Conclusion::Compared with TIVOLI BP-SES, the MiStent system was superior in in-stent LLL at 9 months and had a comparable clinical benefit at 1 year in de novo coronary lesions.

Objective::Data comparing the outcomes of MiStent (Micell Technologies, Durham, North Carolina, USA) microcrystalline biodegradable polymer (BP) drug-eluting stent (DES) and those of another post-marketing BP-DES, TIVOLI (EssenTech, Beijing, China) are rare. This study sought to compare the angiographic efficacy and clinical outcomes of the microcrystalline BP sirolimus-eluting stent (SES) system MiStent and those of TIVOLI BP-SES.Methods::The DESSOLVE-C trial was a prospective, single-blinded, multicenter, randomized trial (NCT02448524), which randomly assigned patients with de novo coronary lesions to receive MiStent or TIVOLI BP-SES by a 1:1 ratio. The primary endpoint was a non-inferiority comparison of in-stent late lumen loss (LLL) by quantitative coronary angiography at 9 months. The secondary endpoint was device-related clinical cardiovascular composite events (target lesion failure (TLF), composite of cardiac death, target vessel myocardial infarction (MI), and clinically driven target lesion revascularization) and 1-year outcomes. Results::A total of 428 patients (216 patients in the MiStent group and 212 patients in the TIVOLI group) were enrolled and included in an intention-to-treat analysis. MiStent was not only non-inferior but superior to TIVOLI for in-stent LLL at 9 months ((0.23 ± 0.37) mm vs. (0.34 ± 0.48) mm, P for non-inferiority <0.001, P for superiority = 0.02). Although without significant difference, the rate of TLF in MiStent was quantitatively lower than that in TIVOLI (3.70% vs. 6.60%; P = 0.17). Conclusion::Compared with TIVOLI BP-SES, the MiStent system was superior in in-stent LLL at 9 months and had a comparable clinical benefit at 1 year in de novo coronary lesions.

Osteoporotic thoracolumbar fracture in the elderly will seriously reduce their quality of life and life expectancy. For osteoporotic thoracolumbar fracture in the elderly, spinal reconstruction is necessary, which should comprehensively consider factors such as the physical condition, fracture type, clinical characteristics and osteoporosis degree. While there lacks relevant clinical norms or guidelines on selection of spinal reconstruction strategies. In order to standardize the concept of spinal reconstruction for osteoporotic thoracolumbar fracture in the elderly, based on the principles of scientificity, practicality and progressiveness, the authors formulated the Clinical guideline for spinal reconstruction of osteoporotic thoracolumbar fracture in elderly patients ( version 2022), in which suggestions based on evidence of evidence-based medicine were put forward upon 10 important issues related to the fracture classification, non-operative treatment strategies and surgical treatment strategies in spinal reconstruction after osteoporosis thoracolumbar fracture in the elderly, hoping to provide a reference for clinical treatment.

Objective: To investigate the expression of lncRNA LINC00886 in human esophageal squamous cell carcinoma (ESCC) tissues and cell lines, and its effects on proliferation, migration and invasion of Eca109 cells. Methods: The cancer tissues and corresponding para-cancerous tissues of 69 ESCC patients were collected in the biological specimen bank of the Fourth Hospital of Hebei Medical University from June 2014 to December 2016; the ESCC cell lines Eca109, TE13, TE1, Kyse150, Yes-2 and Kyse170 were also collected. LINC00886 gene expression in ESCC tissues and cell lines was detected by qPCR. Eca109 cells were transfected with pIRES2-LINC00886 and pIRES2-NC, respectively, and the overexpression efficiency of LINC00886 gene in Eca109 cells was detected by qPCR; MTS, clone formation assay, wound-healing assay and Transwell invasion assay were respectively used to detect the effect of LINC00886 over-expression on proliferation, migration and invasion ability of Eca109 cells. Results: The expression of LINC00886 gene in ESCC tissues was significantly lower than that in para-cancerous tissues (P<0.01), and its expression level was associated with tumor TNM stage and lymph node metastasis (both P<0.05). The expression level of LINC00886 gene in ESCC cell lines was also lower than that of the control group (all P<0.01). Compared with control group, the expression level of LINC00886 gene was significantly higher in Eca109 cells transfected with pIRES2-LINC00886 (both P<0.05). Compared with the control group, LINC00886 overexpression significantly inhibited the proliferation, migration and invasion abilities of Eca109 cells (all P<0.01). Conclusion: The decreased expression of LINC00886 gene may be related to the occurrence and development of ESCC. Over-expression of LINC00886 gene inhibits the proliferation, migration and invasion abilities of ESCC cells.